← Back
Data updated: Mar 10, 2026
SANTEN
OphthalmologyCardiovascular
SANTEN is a pharmaceutical company focused on Ophthalmology, Cardiovascular.
1999
Since
3
Drugs
-
Trials
0
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
No recent activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 54%
0 drugs Phase 3: 12 Phase 2: 6 Phase 1: 2
Cardiovascular 46%
0 drugs Phase 3: 11 Phase 2: 4
Pipeline Strength Pro
Loading...